Proteogenomic characterization of human colon cancer reveals novel therapeutic opportunities
We performed an unprecedented characterization of human colon cancer and paired normal samples with comprehensive integration of data from seven omics platforms. We confirmed previously described benefits of protegenomic integration in human cancer studies and further demonstrated its utility in revealing novel therapeutic opportunities. Comparative proteomic and phosphoproteomic analyses of paired tumor and adjacent normal samples produced a comprehensive catalogue of colon cancer-associated proteins, phosphosites, and kinase activities, including known and putative biomarkers, drug targets, and cancer-testis (CT) antigens. Proteogenomic integration not only prioritized genomically inferred targets such as somatic copy number drivers and somatic mutation-derived neoantigens, but also yielded unexpected discovery of signaling and metabolic targets for specific colon cancers.